\
&
Contact us
\
&
Contact us
Published on | 3 years ago
Programmes
Destination 2 'Environment & health' - HORIZON-HLTH-2024-ENVHLTH-02-two-stage (closed on 19 September 2023)
For the first stage, 90 proposals were submitted under topic HORIZON-HLTH-2024-ENVHLTH-02-06-two-stage.
Destination 4 'Ensuring access to innovative, sustainable and high-quality health care' - HORIZON-HLTH-2024-CARE-04-two-stage (closed on 19 September 2023)
For the first stage, 93 proposals were submitted under topic HORIZON-HLTH-2024-CARE-04-04-two-stage.
For all the above mentioned calls the evaluation results are expected to be communicated on 24 January 2024 at the earliest.
Source: Funding and Tender Portal
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
